

Substitute for form 1448A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(use as many sheets as necessary)**

Sheet

1

**C**

2

**Complete if Known**

<b>Application Number</b>	<b>10/659,501</b>
<b>Filing Date</b>	<b>Sept. 10, 2003</b>
<b>First Named Inventor</b>	<b>Faour, J.</b>
<b>Group Art Unit</b>	<b>1614</b>
<b>Examiner Name</b>	<b>N/A</b>
<b>Attorney Docket Number</b>	<b>MCP-1</b>

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PL	A	WO	97/14711	A1	RECEPTAGEN CORP.	04/24/2001		
	B	WO	98/08859	A1	UNIV. OF UTAH	03/05/1998		
	C	WO	99/65930	A1	BIOTECH AUSTRALIA	12/23/1999		
	D	WO	00/62808	A2	MAYO FOUNDATION	10/26/2000		
	E	WO	00/33810	A1	BIOVECTOR THERAP.	08/15/2000		
	F	WO	00/56404	A1	KILGOWAN LTD.	09/28/2000		
	G	WO	01/28592	A1	MAYO FOUNDATION	04/26/2001		
	H	WO	01/28595	A1	MAYO FOUNDATION	04/26/2001		
	I	WO	01/30967	A1	UNIV. OF UTAH	05/03/2001		
	J	WO	02/074171	A1	UNIV. OF UTAH	09/26/2002		
	K	WO	03/025139	A1	MAYO FOUNDATION	03/27/2003		
PL	L	WO	03/026674	A1	MAYO FOUNDATION	04/03/2003		
	M	EP	0220030	B1	BIOTECH AUSTRALIA	04/29/1987		
	N	GB	944428	B1	MERCK & CO.	12/11/1963		

**Examiner  
Signature**

**Date Considered**

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>1</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer.

Under the Paperwork Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/659,501
		Filing Date	09/10/2003
		First Named Inventor	Weinshenker, N. et al.
		Group Art Unit	1614
		Examiner Name	N/A
Sheet 2	of 2	Attorney Docket Number	MCP-1

OTHER - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	-2
PL	P	P.L. CARL ET AL.; "A novel connector linkage applicable in prodrug design"; J. Med. Chem. (1981), 24(5), pp.479-480.	
PL	Q	B.E. TOKI ET AL.; "Protease-mediated fragmentation of p-amidobenzyl ethers: A new strategy for the activation of anticancer drugs"; J. Org. Chem. (2002), 67(6), pp. 1866-1872.	

Examiner Signature		Date Considered	8-31-05
-----------------------	---	--------------------	---------

# ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

<b>Title of Invention</b>	Cobalamin conjugates for anti-tumor therapy
---------------------------	---

Application Number : 10/659501



Confirmation Number: 7515

First Named Applicant: Ned Weinshenker

Attorney Docket Number: MCP-1

Art Unit: 1614

Examiner:

Search string: ( 5863900 or 6262253 or 5807832 or 5739287 or 5589463 or 6315978 or 5428023 or 6083926 or 3130189 or 5449720 or 5548064 or 5869466 or 6150341 ).pn

## US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
PL	1	5863900	1999-01-26	Russell-Jones	A1	514	15
	2	6262253	2001-07-17	Russell-Jones	A1	536	26.41
	3	5807832	1998-09-15	Russell-Jones	A1	514	21
	4	5739287	1998-04-14	Wilbur	A1	530	367
	5	5589463	1996-12-31	Russell-Jones	A1	514	21
	6	6315978	2001-11-13	Grissom	A1	424	1.53
	7	5428023	1995-06-27	Russell-Jones	A1	514	21
	8	6083926	2000-07-04	Morgan Jr.	A1	514	52
	9	3130189	1964-04-21	Hannus	A1	260	112
	10	5449720	1995-09-12	Russell-Jones	A1	525	54.1
	11	5548064	1996-04-20	Russell-Jones	A1	530	380
W	12	5869466	1999-02-09	Russell-Jones	A1	514	52
PL	13	6150341	2000-11-21	Russell-Jones	A1	514	52


## Remarks

Note: Remarks are not for responding to an office action.

Applicants hereby submit the present INFORMATION DISCLOSURE STATEMENT. Applicants submit herewith patents, publications or other information which may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 CFR 1.56(g)), or as an admission that the

information cited is, or is considered to be, material to patentability. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. It is respectfully requested that the references identified in this Information Disclosure Statement be considered by the Examiner, be made a part of the official record, and be cited in the issued patent. The person making this statement is the agent on the basis of information in the agent's file.

**Signature**

Examiner Name	Date
	8-31-05

# ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

## Title of Invention

Cobalamin conjugates for anti-tumor therapy

Application Number : 10/659501  
Confirmation Number: 7515  
First Named Applicant: Ned Weinshenker  
Attorney Docket Number: MCP-1  
Art Unit: 1614



Examiner:

Search string: ( 5574018 or 5840880 or 5840712 or 5869465 or 6214345 or 6315978 or 5405839 or 20020192683 or 20020115595 or 20020049154 or 20020111294 or 20020151525 or 20020049155 or 20020042394 ).pn

## US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
PL	1	5574018	1996-11-12	Habberfield	A1	514	21
I	2	5840880	1998-11-24	Morgan	A1	536	26.4
I	3	5840712	1998-11-24	Morgan	A1	514	52
I	4	5869465	1999-02-09	Morgan	A1	514	52
I	5	6214345	2001-04-10	Firestone	A1	424	178.1
↓	6	6315978	2001-11-13	Grissom	A1	424	1.53
PL	7	5405839	1995-04-11	Toraya	A1	514	52

## US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications


init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
PL	1	20020192683	2002-12-19	Grissom	A1	435	6
I	2	20020115595	2002-08-22	Grissom	A1	514	6
I	3	20020049154	2002-04-25	Grissom	A1	514	6
I	4	20020111294	2002-08-15	Grissom	A1	514	6
I	5	20020151525	2002-10-17	Collins	A1	514	80
↓	6	20020049155	2002-04-25	Hogenkamp	A1	514	7
PL	7	20020042394	2002-04-11	Hogenkamp	A1	514	53

## Remarks

Note: Remarks are not for responding to an office action.

Applicants hereby submit the present INFORMATION DISCLOSURE STATEMENT. Applicants submit herewith patents, publications or other information which may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 CFR 1.56(g)), or as an admission that the information cited is, or is considered to be, material to patentability. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. It is respectfully requested that the references identified in this Information Disclosure Statement be considered by the Examiner, be made a part of the official record, and be cited in the issued patent. The person making this statement is the agent on the basis of information in the agent's file.

## Signature

Examiner Name	Date
	8-31-05